Is the worst over? Catalent touts GLP-1 and gene therapy business as it sticks to financial guidance

Catal­ent’s fi­nan­cial health ap­pears to be on the mend thanks to spe­cif­ic seg­ments of its man­u­fac­tur­ing busi­ness, but the CD­MO still has a long road to re­cov­ery.

In a sur­prise to an­a­lysts and ob­servers, Catal­ent reaf­firmed its full fis­cal 2024 guid­ance, fore­cast­ing rev­enue of $4.3 bil­lion to $4.5 bil­lion. Part of the growth fore­cast for 2024 is at­trib­uted to a string of new an­tic­i­pat­ed reg­u­la­to­ry ap­provals for ther­a­pies which it is con­tract­ed to man­u­fac­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.